RecruitingNCT07256015

Deucravacitinib for Patients With Moderate/Severe Psoriasis: A Real-Life Experience in Italy

"DEMOS" - Deucravacitinib for Patients With Moderate/Severe Psoriasis: A Real-Life Experience in Italy

Sponsor

Bristol-Myers Squibb

Enrollment

200 participants

Start Date

Aug 5, 2025

Study Type

OBSERVATIONAL

Conditions

Psoriasis

Summary

The purpose of this study is to characterize the real-life experience of patients with moderate/severe psoriasis receiving deucravacitinib treatment, in terms of efficacy, safety, and health-related quality of life (HRQoL) in Italy

Eligibility

Min Age: 18 Years

Inclusion Criteria3

Participants have initiated treatment with deucravacitinib monotherapy 4 to 8 weeks earlier according to clinical practice and to reimbursement criteria determined by National Drug Agency in Italy (AIFA)
Patients have moderate to severe plaque psoriasis
Patients have signed informed consent form (ICF)

Exclusion Criteria2

Simultaneous participation in any interventional study for their moderate-to-severe psoriasis
Inability to participate to the study for the following reasons: patients unable to understand the aim of the study, patients unable to understand and sign the ICF

Interventions

DRUGDeucravacitinib

According to the product label

Locations(1)

Azienda Ospedaliera Universitaria Integrata Di Verona

Verona, Verona, Italy

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07256015

Related Trials

Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer

NCT0381634552 locations

Unhide® Project: A Digital Health Platform to Collect Lifestyle Data for Brain Inflammation Research

NCT048066201 location

Is There a Benefit From Addition of Treadmill Walking to Diet Restriction in Psoriasis Women With PCOS?

NCT072893991 location

Testing of an Educational Tool for Patients With Melanoma and Pre-Existing Autoimmune Disease Who Are Candidates for Immune Checkpoint Inhibitors

NCT047513961 location

Prevalence and Risk Factors asSOciated With CArdiac comorbiDIty in psoriAsis

NCT049502181 location